Regular ArticlesCYTOKINE EXPRESSION IN THREE MOUSE MODELS OF EXPERIMENTAL HEPATITIS
References (26)
- et al.
Pathophysiological mechanisms of TNF during intoxication with natural or man-made toxins (Review)
Toxicology
(1999) Pathogenesis of autoimmune hepatitis
Biomed Pharmacother
(1999)- et al.
Concanavalin A-induced T cell-mediated hepatic injury in mice: the role of tumor necrosis factor
Hepatology
(1995) - et al.
Interferon-γ plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A
Gastroenterology
(1996) - et al.
Critical involvement of interferon γ in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis
Hepatology
(1996) - et al.
Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism
Hepatology
(2000) - et al.
Interleukin-10 inhibits hepatic injury and tumor necrosis factor-alpha and interferon-gamma mRNA expression induced by staphylococcal enterotoxin B or lipopolysaccharide in galactosamine-sensitized mice
J Hepatol
(1999) - et al.
Importance of Kupffer cells for T cell-dependent liver injury in mice
Am J Pathol
(2000) - et al.
A T-cell dependent experimental liver injury in mice inducible by concanavalin A
J Clin Invest
(1992) - et al.
DNA fragmentation in mouse organs during endotoxic shock
Am J Pathol
(1996)
Cytokines in viral hepatitis
Semin Liver Dis
T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6
J Exp Med
Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice
Hepatology
Cited by (192)
Pathogenesis of Concanavalin A induced autoimmune hepatitis in mice
2022, International ImmunopharmacologyTaraxasterol mitigates Con A-induced hepatitis in mice by suppressing interleukin-2 expression and its signaling in T lymphocytes
2022, International ImmunopharmacologyCitation Excerpt :These results indicate that TAS protected the liver from Con A-induced injury resulting in reduced severity of hepatitis. Supporting previous studies [18], our data showed that Con A treatment greatly increased the productions of IL-2, IL-6, TNF-α and IFN-γ in the serum of Con A group as compared with that of control, while TAS treatment suppressed the production of these cytokines except IFN-γ (Fig. 2A–D). Different from IL-6, TNF-α and IFN-γ, basal levels of IL-4 and IL-17A (without Con A stimulation) could be detected in the mouse sera.
Interleukin-35: An emerging player in the progression of liver diseases
2021, Clinics and Research in Hepatology and Gastroenterology
- f1
Correspondence to: Address correspondence to: Gisa Tiegs, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Fahrstrasse 17, D-91054 Erlangen, Germany. Tel: +49-9131-85 22 883; Fax: +49-9131-85 22 774; E-mail: [email protected]